In a nutshell This trial explored the effect of bosutinib (Bosulif) on the long-term health-related quality of life of chronic myeloid leukemia patients who did not respond to other treatments. This study concluded that bosutinib did not significantly affect long-term health-related quality of life. Some background Tyrosine kinase inhibitors...
Read More
In a nutshell This study compared the effectiveness of two types of tyrosine kinase inhibitors – imatinib (Gleevac) and radotinib (Supect) – for chronic myeloid leukemia (CML). Researchers concluded that response to treatment occurred sooner and more strongly with radotinib than with imatinib. Some background Tyrosine kinase...
Read MoreIn a nutshell This study examined a side effect called pleural effusion (PE; fluid build-up in the lungs) in patients with chronic myeloid leukemia (CML) treated with dasatinib (Sprycel). PE occurred in 23% of patients. This study concluded that reducing the dose of dasatinib after the first occurrence of PE did not prevent a recurrence. Some...
Read MoreIn a nutshell This study aimed to investigate the incidence of pulmonary hypertension in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. This study concluded that treating CML patients with tyrosine kinase inhibitors can lead to mild pulmonary hypertension. Some background Tyrosine kinase inhibitors (TKIs) are a...
Read More
In a nutshell This study examined treatment combinations involving imatinib (Gleevec) for chronic myeloid leukemia (CML). Researchers concluded that treatment with standard-dose imatinib achieved a survival comparable to that of the general population. Patient disease factors affected outcomes more than initial treatment selection. Some background...
Read MoreIn a nutshell This study examined whether treatment with tyrosine kinase inhibitors (TKIs) can be successfully discontinued after a failed first attempt in patients with chronic myeloid leukemia (CML). Researchers reported that a second TKI discontinuation attempt is safe and can be successful after a failed first attempt. Some background Targeted...
Read MoreIn a nutshell This study reviewed evidence on patients with chronic lymphocytic leukemia (CLL) that stop responding to ibrutinib (Imbruvica) therapy. Some background Tyrosine kinase inhibitor therapy is a targeted therapy that blocks signals needed for tumors to grow. This includes the Bruton tyrosine kinase inhibitor ibrutinib. Ibrutinib blocks a...
Read More
In a nutshell This study aimed to investigate atrial fibrillation as a side effect of ibrutinib (imbruvica) in chronic lymphocytic leukemia. This study concluded that atrial fibrillation is a common side effect associated with ibrutinib use in patients with chronic lymphocytic leukemia. Some background Chronic lymphocytic leukemia (CLL)...
Read More
In a nutshell This study examined the effect of early treatment response to different tyrosine kinase inhibitors on long-term outcomes in patients with chronic myeloid leukemia (CML). Researchers reported that early treatment response is predictive of long-term outcomes across all tyrosine kinase inhibitors studied. Some background CML is a...
Read More
In a nutshell This study examined the extent and effect of complete treatment response (on a molecular level) in patients treated with imatinib (Gleevac) for chronic myeloid leukemia (CML). Researchers reported that a high proportion of patients treated with imatinib reached complete molecular remission, particularly when given at a high dose. Complete...
Read More
